138
Participants
Start Date
April 17, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2026
TQB3909 Tablets + Azacitidine
TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue
NOT_YET_RECRUITING
Affiliated Hospital of Chengde Medical University, Chengde
NOT_YET_RECRUITING
Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing
NOT_YET_RECRUITING
Peking University People's Hospital, Beijing
NOT_YET_RECRUITING
Beijing Tsinghua Changgung Hospital, Beijing
NOT_YET_RECRUITING
Shengjing Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Harbin The First Hospital, Harbin
RECRUITING
ShangHai Tongren Hospital, Shanghai
NOT_YET_RECRUITING
Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital, Shanghai
NOT_YET_RECRUITING
Shanghai Pudong New Area People's Hospital, Shanghai
NOT_YET_RECRUITING
The First Affiliated Hospital of Bengbu Medical University, Bengbu
NOT_YET_RECRUITING
Zibo Central Hospital, Zibo
NOT_YET_RECRUITING
Tai'an Central Hospital (Tai'an Central Hospital affiliated to Qingdao University, Mount Taishan Medical Center), Taian
NOT_YET_RECRUITING
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
NOT_YET_RECRUITING
People's Hospital of Tianjin (City), Tianjin
NOT_YET_RECRUITING
The First Affiliated Hospital of Ningbo University, Ningbo
NOT_YET_RECRUITING
Zhuzhou Central Hospita, Zhuzhou
NOT_YET_RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
NOT_YET_RECRUITING
Henan Provincial People's Hospital, Zhengzhou
NOT_YET_RECRUITING
People's hospital of deyang city, Deyang
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an
NOT_YET_RECRUITING
The First Affiliated Hospital of Xinjiang Medical University, Ürümqi
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY